Epilepsy – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Epilepsy – Pipeline Review, H2 2019’, provides an overview of the Epilepsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Epilepsy

– The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects

– The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Epilepsy”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Epilepsy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Aadi Bioscience Inc

Advanced Neural Dynamics Inc

Advicenne SA

Aequus Pharmaceuticals Inc

Aevi Genomic Medicine Inc

AfaSci Inc

Affectis Pharmaceuticals AG

AMO Pharma Ltd

Anavex Life Sciences Corp

Aphios Corp

Aquestive Therapeutics Inc

Asklepios BioPharmaceutical Inc

Aucta Pharmaceuticals LLC

AurimMed Pharma Inc

Axium Pharmaceuticals Inc

B&A Therapeutics

BCWorld Pharm Co Ltd

Bial – Portela & Ca SA

Bio-Pharm Solutions Co Ltd

BioElectron Technology Corp

Biogen Inc

BioHealthonomics Inc

BioLink Life Sciences Inc

BioPharmartis

Biovista Inc

Bloom Science Inc

Bod Australia Ltd

Cann Pharmaceutical Australia Ltd

Catalyst Pharmaceuticals Inc

Cavion LLC

Celgene Corp

Cellix Bio Pvt Ltd

Cerebral Therapeutics Inc

Cerecin Inc

Cerecor Inc

Cerevel Therapeutics LLC

Coda Biotherapeutics Inc

CombiGene AB

Crossject SA

CuroNZ Ltd

CURx Pharmaceuticals Inc

Cypralis Ltd

EastGate Pharmaceuticals Inc

Eisai Co Ltd

Encoded Therapeutics Inc

Engage Therapeutics Inc

Epalex Corp

EpyGenix Therapeutics Inc

Eton Pharmaceuticals Inc

GABA Therapeutics Inc

Genus Lifesciences Inc

Gilead Sciences Inc

Glialogix Inc

Guangzhou Cellprotek Pharmaceutical Co Ltd

GW Pharmaceuticals Plc

Harvest One Cannabis Inc

Idorsia Pharmaceutical Ltd

Insys Therapeutics Inc

INVENT Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Iproteos SL

JC Pharma Inc

Johnson & Johnson

Karessa Pharma Holding AB

Ketogen Inc

Knopp Biosciences LLC

Lead Discovery Center GmbH

LifeSplice Pharma LLC

Marinus Pharmaceuticals Inc

Medicure Inc

Medlab Clinical Ltd

Mercaptor Discoveries Inc

MGC Pharmaceuticals Ltd

Mucodel Pharma LLC

MyX Therapeutics Inc

NeuCyte Inc

NeurAegis Inc

Neurelis Inc

NeuroAdjuvants Inc

Neurocrine Biosciences Inc

NeuroCycle Therapeutics GmbH

Neuroene Therapeutics LLC

Neurolink, Inc

Neuron Biopharma SA

Neurona Therapeutics Inc

New Amsterdam Sciences Inc

Nissan Chemical Corp

NoNO Inc

Novartis AG

NuBioPharma LLC

OB Pharmaceuticals

OPKO Health Inc

Ovid Therapeutics Inc

OWP Pharmaceuticals Inc

Pairnomix LLC

Panaxia Pharmaceutical Industries Ltd

Panorama Research Inc

Pfizer Inc

PharmatrophiX Inc

Praxis Precision Medicines Australia Pty Ltd

Promius Pharma LLC

Proniras Corp

Proveca Ltd

PTC Therapeutics Inc

Recursion Pharmaceuticals Inc

reMYND NV

RogCon Inc

Sage Therapeutics Inc

Saniona AB

Scientus Pharma Inc

Sedor Pharmaceuticals LLC

Serina Therapeutics Inc

Simcere Pharmaceutical Group

SK Biopharmaceuticals Co Ltd

Stoke Therapeutics Inc

Suda Pharmaceuticals Ltd

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Supernus Pharmaceuticals Inc

Sustained Nano Systems LLC

Taho Pharmaceuticals Ltd

Takeda Pharmaceutical Co Ltd

Techfields Pharma Co Ltd

The Cell Factory BVBA

Therapix Biosciences Ltd

UCB SA

Ultragenyx Pharmaceutical Inc

Valerion Therapeutics LLC

VistaGen Therapeutics Inc

Vitality Biopharma Inc

Xenon Pharmaceuticals Inc

XERIS Pharmaceuticals Inc

Xi’an Libang Pharmaceuticals Co Ltd

XW Laboratories Inc

Zhejiang Conba Pharmaceutical Co Ltd

Zogenix Inc

Zynerba Pharmaceuticals Inc”

Table of Contents

Table of Contents

Introduction

Epilepsy Overview

Epilepsy Therapeutics Development

Epilepsy Therapeutics Assessment

Epilepsy Companies Involved in Therapeutics Development

Epilepsy Drug Profiles

Epilepsy Dormant Projects

Epilepsy Discontinued Products

Epilepsy Product Development Milestones

Appendix

List of Tables

“List of Tables

Number of Products under Development for Epilepsy, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Epilepsy – Pipeline by Aadi Bioscience Inc, H2 2019

Epilepsy – Pipeline by Advanced Neural Dynamics Inc, H2 2019

Epilepsy – Pipeline by Advicenne SA, H2 2019

Epilepsy – Pipeline by Aequus Pharmaceuticals Inc, H2 2019

Epilepsy – Pipeline by Aevi Genomic Medicine Inc, H2 2019

Epilepsy – Pipeline by AfaSci Inc, H2 2019

Epilepsy – Pipeline by Affectis Pharmaceuticals AG, H2 2019

Epilepsy – Pipeline by AMO Pharma Ltd, H2 2019

Epilepsy – Pipeline by Anavex Life Sciences Corp, H2 2019

Epilepsy – Pipeline by Aphios Corp, H2 2019

Epilepsy – Pipeline by Aquestive Therapeutics Inc, H2 2019

Epilepsy – Pipeline by Asklepios BioPharmaceutical Inc, H2 2019

Epilepsy – Pipeline by Aucta Pharmaceuticals LLC, H2 2019

Epilepsy – Pipeline by AurimMed Pharma Inc, H2 2019

Epilepsy – Pipeline by Axium Pharmaceuticals Inc, H2 2019

Epilepsy – Pipeline by B&A Therapeutics, H2 2019

Epilepsy – Pipeline by BCWorld Pharm Co Ltd, H2 2019

Epilepsy – Pipeline by Bial – Portela & Ca SA, H2 2019

Epilepsy – Pipeline by Bio-Pharm Solutions Co Ltd, H2 2019

Epilepsy – Pipeline by BioElectron Technology Corp, H2 2019

Epilepsy – Pipeline by Biogen Inc, H2 2019

Epilepsy – Pipeline by BioHealthonomics Inc, H2 2019

Epilepsy – Pipeline by BioLink Life Sciences Inc, H2 2019

Epilepsy – Pipeline by BioPharmartis, H2 2019

Epilepsy – Pipeline by Biovista Inc, H2 2019

Epilepsy – Pipeline by Bloom Science Inc, H2 2019

Epilepsy – Pipeline by Bod Australia Ltd, H2 2019

Epilepsy – Pipeline by Cann Pharmaceutical Australia Ltd, H2 2019

Epilepsy – Pipeline by Catalyst Pharmaceuticals Inc, H2 2019

Epilepsy – Pipeline by Cavion LLC, H2 2019

Epilepsy – Pipeline by Celgene Corp, H2 2019

Epilepsy – Pipeline by Cellix Bio Pvt Ltd, H2 2019

Epilepsy – Pipeline by Cerebral Therapeutics Inc, H2 2019

Epilepsy – Pipeline by Cerecin Inc, H2 2019

Epilepsy – Pipeline by Cerecor Inc, H2 2019

Epilepsy – Pipeline by Cerevel Therapeutics LLC, H2 2019

Epilepsy – Pipeline by Coda Biotherapeutics Inc, H2 2019

Epilepsy – Pipeline by CombiGene AB, H2 2019

Epilepsy – Pipeline by Crossject SA, H2 2019

Epilepsy – Pipeline by CuroNZ Ltd, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Epilepsy, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Top 10 Routes of Administration, H2 2019

Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Number of Products by Top 10 Molecule Types, H2 2019

Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports